S&P 500   4,586.24 (+1.05%)
DOW   35,206.06 (+1.81%)
QQQ   383.58 (+0.12%)
AAPL   165.93 (+2.53%)
MSFT   322.49 (-0.16%)
FB   314.70 (+2.56%)
GOOGL   2,838.86 (-0.04%)
AMZN   3,421.98 (+0.95%)
TSLA   979.12 (-3.53%)
NVDA   292.88 (-4.58%)
BABA   120.44 (+7.57%)
NIO   31.82 (-1.03%)
CGC   9.93 (-0.60%)
AMD   135.90 (-5.63%)
GE   96.58 (+4.11%)
MU   81.92 (+0.37%)
T   23.54 (+0.34%)
F   19.20 (+0.31%)
DIS   150.16 (+2.69%)
PFE   52.32 (-3.59%)
AMC   28.59 (-1.45%)
ACB   5.86 (+0.69%)
BA   205.68 (+3.62%)
S&P 500   4,586.24 (+1.05%)
DOW   35,206.06 (+1.81%)
QQQ   383.58 (+0.12%)
AAPL   165.93 (+2.53%)
MSFT   322.49 (-0.16%)
FB   314.70 (+2.56%)
GOOGL   2,838.86 (-0.04%)
AMZN   3,421.98 (+0.95%)
TSLA   979.12 (-3.53%)
NVDA   292.88 (-4.58%)
BABA   120.44 (+7.57%)
NIO   31.82 (-1.03%)
CGC   9.93 (-0.60%)
AMD   135.90 (-5.63%)
GE   96.58 (+4.11%)
MU   81.92 (+0.37%)
T   23.54 (+0.34%)
F   19.20 (+0.31%)
DIS   150.16 (+2.69%)
PFE   52.32 (-3.59%)
AMC   28.59 (-1.45%)
ACB   5.86 (+0.69%)
BA   205.68 (+3.62%)
S&P 500   4,586.24 (+1.05%)
DOW   35,206.06 (+1.81%)
QQQ   383.58 (+0.12%)
AAPL   165.93 (+2.53%)
MSFT   322.49 (-0.16%)
FB   314.70 (+2.56%)
GOOGL   2,838.86 (-0.04%)
AMZN   3,421.98 (+0.95%)
TSLA   979.12 (-3.53%)
NVDA   292.88 (-4.58%)
BABA   120.44 (+7.57%)
NIO   31.82 (-1.03%)
CGC   9.93 (-0.60%)
AMD   135.90 (-5.63%)
GE   96.58 (+4.11%)
MU   81.92 (+0.37%)
T   23.54 (+0.34%)
F   19.20 (+0.31%)
DIS   150.16 (+2.69%)
PFE   52.32 (-3.59%)
AMC   28.59 (-1.45%)
ACB   5.86 (+0.69%)
BA   205.68 (+3.62%)
S&P 500   4,586.24 (+1.05%)
DOW   35,206.06 (+1.81%)
QQQ   383.58 (+0.12%)
AAPL   165.93 (+2.53%)
MSFT   322.49 (-0.16%)
FB   314.70 (+2.56%)
GOOGL   2,838.86 (-0.04%)
AMZN   3,421.98 (+0.95%)
TSLA   979.12 (-3.53%)
NVDA   292.88 (-4.58%)
BABA   120.44 (+7.57%)
NIO   31.82 (-1.03%)
CGC   9.93 (-0.60%)
AMD   135.90 (-5.63%)
GE   96.58 (+4.11%)
MU   81.92 (+0.37%)
T   23.54 (+0.34%)
F   19.20 (+0.31%)
DIS   150.16 (+2.69%)
PFE   52.32 (-3.59%)
AMC   28.59 (-1.45%)
ACB   5.86 (+0.69%)
BA   205.68 (+3.62%)
NASDAQ:AMRN

Amarin Stock Forecast, Price & News

$3.54
-0.03 (-0.84%)
(As of 12/6/2021 12:02 PM ET)
Add
Compare
Today's Range
$3.50
$3.58
50-Day Range
$3.56
$5.38
52-Week Range
$3.46
$9.25
Volume
98,356 shs
Average Volume
4.64 million shs
Market Capitalization
$1.40 billion
P/E Ratio
89.25
Dividend Yield
N/A
Beta
2.18
30 days | 90 days | 365 days | Advanced Chart
Receive AMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter.


Amarin logo

About Amarin

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Headlines

Amarin (NASDAQ:AMRN) Reaches New 12-Month Low at $3.57
November 29, 2021 |  americanbankingnews.com
Amarin (NASDAQ:AMRN) Hits New 1-Year Low at $3.83
November 22, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AMRN
Fax
N/A
Employees
2,020
Year Founded
1991

Sales & Book Value

Annual Sales
$614.06 million
Book Value
$1.62 per share

Profitability

Net Income
$-18 million
Pretax Margin
0.41%

Debt

Price-To-Earnings

Miscellaneous

Free Float
385,257,000
Market Cap
$1.40 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/03/2021
Today
12/06/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/24/2022

Social Links


MarketRank

Overall MarketRank

1.79 out of 5 stars

Medical Sector

855th out of 1,390 stocks

Pharmaceutical Preparations Industry

412th out of 672 stocks

Analyst Opinion: 3.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Amarin (NASDAQ:AMRN) Frequently Asked Questions

Is Amarin a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Amarin stock.
View analyst ratings for Amarin
or view top-rated stocks.

How has Amarin's stock price been impacted by Coronavirus (COVID-19)?

Amarin's stock was trading at $12.56 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AMRN stock has decreased by 71.6% and is now trading at $3.57.
View which stocks have been most impacted by COVID-19
.

When is Amarin's next earnings date?

Amarin is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Amarin
.

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) announced its quarterly earnings data on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.04) by $0.01. The biopharmaceutical company had revenue of $142 million for the quarter, compared to analyst estimates of $161.29 million. Amarin had a negative net margin of 0.34% and a positive trailing twelve-month return on equity of 1.89%. The company's revenue was down 8.5% compared to the same quarter last year. During the same quarter last year, the company earned ($0.02) EPS.
View Amarin's earnings history
.

What price target have analysts set for AMRN?

5 equities research analysts have issued 1-year price objectives for Amarin's stock. Their forecasts range from $5.00 to $19.00. On average, they anticipate Amarin's stock price to reach $10.50 in the next year. This suggests a possible upside of 194.1% from the stock's current price.
View analysts' price targets for Amarin
or view top-rated stocks among Wall Street analysts.

Who are Amarin's key executives?

Amarin's management team includes the following people:
  • Karim Mikhail, President, Chief Executive Officer & Director
  • Derek Kalinowski, SVP-Manufacturing Operations
  • Michael W. Kalb, Chief Financial Officer & Senior Vice President (LinkedIn Profile)
  • Steven B. Ketchum, Chief Scientific Officer & Senior Vice President
  • Rebecca Juliano, Senior VP-Clinical Research & Development

What is John Thero's approval rating as Amarin's CEO?

10 employees have rated Amarin CEO John Thero on Glassdoor.com. John Thero has an approval rating of 93% among Amarin's employees. This puts John Thero in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), (CGC), Square (SQ), Alibaba Group (BABA), Tesla (TSLA), Bank of America (BAC), Netflix (NFLX) and Novavax (NVAX).

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

Who are Amarin's major shareholders?

Amarin's stock is owned by a variety of retail and institutional investors. Top institutional investors include Eversept Partners LP (2.94%), BVF Inc. IL (2.89%), Sarissa Capital Management LP (2.15%), Morgan Stanley (1.60%), DG Capital Management LLC (1.02%) and Private Advisor Group LLC (0.39%). Company insiders that own Amarin stock include David M Stack, John F Thero, Michael Wayne Kalb and Steven B Ketchum.
View institutional ownership trends for Amarin
.

Which institutional investors are selling Amarin stock?

AMRN stock was sold by a variety of institutional investors in the last quarter, including Eversept Partners LP, Two Sigma Investments LP, Millennium Management LLC, DG Capital Management LLC, Goldman Sachs Group Inc., Geode Capital Management LLC, Caption Management LLC, and Squarepoint Ops LLC. Company insiders that have sold Amarin company stock in the last year include Michael Wayne Kalb, and Steven B Ketchum.
View insider buying and selling activity for Amarin
or view top insider-selling stocks.

Which institutional investors are buying Amarin stock?

AMRN stock was bought by a variety of institutional investors in the last quarter, including BVF Inc. IL, Sarissa Capital Management LP, Private Advisor Group LLC, Verition Fund Management LLC, Gyon Technologies Capital Management LP, Van ECK Associates Corp, Wolverine Trading LLC, and Voloridge Investment Management LLC.
View insider buying and selling activity for Amarin
or or view top insider-buying stocks.

How do I buy shares of Amarin?

Shares of AMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amarin's stock price today?

One share of AMRN stock can currently be purchased for approximately $3.57.

How much money does Amarin make?

Amarin has a market capitalization of $1.41 billion and generates $614.06 million in revenue each year.

How many employees does Amarin have?

Amarin employs 2,020 workers across the globe.

Does Amarin have any subsidiaries?

The following companies are subsidiares of Amarin: Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Limited, Amarin Switzerland GmbH, Amarin UK Limited, Ester Neurosciences, and Ester Neurosciences Limited.

When was Amarin founded?

Amarin was founded in 1991.

What is Amarin's official website?

The official website for Amarin is www.amarincorp.com.

Where are Amarin's headquarters?

How can I contact Amarin?

Amarin's mailing address is 77 Sir John Rogerson`s Quay Block C Grand Canal Docklands, Dublin L2, Dublin 2. The biopharmaceutical company can be reached via phone at (531) 669-9020 or via email at [email protected].


This page was last updated on 12/6/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.